Dr Peter Schneider (University of California, San Francisco, San Francisco, CA, US) discusses Latest results from the IN. PACT clinical programme - Is paclitaxel safe for the treatment of PAD?

Questions :
1. What is the IN. PACT clinical programme and why was it initiated?
2. What were the objectives of the study and key findings?
3. You have collected data on paclitaxel safety in PAD patients from IN.PACT in light of the Katsanos meta-analysis. What does this tell us?    
4. What is required to alleviate safety concerns with paclitaxel coated products?

Interviewer: Mirjam Boros
Videographer: Mike Knight

Filmed on site at CX 2019 by Radcliffe Vascular